Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 6/20 | 0.49 |
| ▸ | PLK1 | P53350 | 3/20 | 0.49 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.38 |
| ▸ | TEC | P42680 | 1/20 | 0.38 |
| ▸ | TXK | P42681 | 1/20 | 0.38 |
| ▸ | BLK | P51451 | 1/20 | 0.38 |
| ▸ | BMX | P51813 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182601 | 1.00 | NEK2 (0.49) | NEK2PLK1RPS6KA5ALDH1A1PKM | |
| SCHEMBL182613 | 0.85 | NEK2 (0.51) | NEK2PLK1RPS6KA5ALDH1A1PKM | |
| SCHEMBL182614 | 0.85 | NEK2 (0.51) | NEK2PLK1RPS6KA5ALDH1A1PKM | |
| SCHEMBL182322 | 0.84 | NEK2 (0.50) | NEK2PLK1RPS6KA5ALDH1A1PKM | |
| SCHEMBL182323 | 0.84 | NEK2 (0.50) | NEK2PLK1RPS6KA5ALDH1A1PKM | |
| SCHEMBL11021835 | 0.82 | NEK2 (0.56) | NEK2PLK1RPS6KA5ALDH1A1PKM | |
| SCHEMBL11021837 | 0.82 | NEK2 (0.56) | NEK2PLK1RPS6KA5ALDH1A1PKM | |
| SCHEMBL10212386 | 0.78 | LRRK2 (0.34) | NEK2PLK1RPS6KA5JAK3MAPT | |
| SCHEMBL182334 | 0.76 | KIF11 (0.42) | ALDH1A1JAK3MAPTKDM4EMEN1 | |
| SCHEMBL560975 | 0.73 | NEK2 (0.77) | NEK2PLK1ALDH1A1ERBB2TEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422263-B2 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9073939-B2 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-8759341-B2 | Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| EP-2485726-B1 | FLUORO-SUBSTITUTED 3,5-DICYANO-4-(1H-INDAZOL-5-YL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-8642595-B2 | Annellated 4-(indazolyl)-1,4-dihydropyridine derivatives and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| EP-2451817-B1 | INDAZOLYL-SUBSTITUTED DIHYDROISOXA-ZOLOPYRIDINES AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-2398790-B1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER IP GMBH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20120270905-A1 | FLUORINATED 2,6-DIALKYL-3,5-DICYANO-4-(1H-INDAZOL-5-YL)-1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120264785-A1 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
| EP-2493873-A1 | FLUORINATED 2,6-DIALKYL-3,5-DICYANO-4-(1H-INDAZOL-5-YL)-1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2012-09-05 | — | — | EP | disclosed |
| EP-2485726-A1 | FLUORO-SUBSTITUTED 3,5-DICYANO-4-(1H-INDAZOL-5-YL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2012-08-15 | — | — | EP | disclosed |
| US-20120190709-A1 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120035409-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | US | disclosed |
| EP-2300482-B1 | ANNELLATED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINE DERIVATIVES AS c-Met MEDIATORS | Bayer Pharma AG (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20110172221-A1 | ANNELLATED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-14 | — | — | US | disclosed |
| WO-2011042368-A1 | FLUORO-SUBSTITUTED 3,5-DICYANO-4-(1H-INDAZOL-5-YL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011042367-A1 | FLUORINATED 2,6-DIALKYL-3,5-DICYANO-4-(1H-INDAZOL-5-YL)-1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270905-A1 | FLUORINATED 2,6-DIALKYL-3,5-DICYANO-4-(1H-INDAZOL-5-YL)-1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | MET, DCK, RET | NEK2 447/4885PLK1 2190/4885RPS6KA5 395/4885 |
| US-20110172221-A1 | ANNELLATED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | MET, ERBB4, RET | NEK2 827/4885PLK1 1039/4885RPS6KA5 654/4885 |
| US-20120035409-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | MET, RET, ERBB2 | NEK2 1049/4885PLK1 1152/4885RPS6KA5 842/4885 |
| US-20120264785-A1 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | MET, DCK, RET | NEK2 906/4885PLK1 2552/4885RPS6KA5 405/4885 |
| US-20120190709-A1 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BMX, MET, ABL1 | NEK2 1730/4885PLK1 3162/4885RPS6KA5 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.